 LEEDS, England--BUSINESS WIRE--4D pharma plc AIM: DDD 4D or the Company, a pharmaceutical company leading the development of Live Biotherapeutic products LBPs, a novel class of drug derived from the microbiome, today announces it has entered into Securities Purchase Agreements with a select group of U.S. and United Kingdom institutional investors and accredited investors to raise, in aggregate, approximately 24.03 million 17.29 million in a private placement the Fundraising 